canagliflozin

(redirected from Invokana)
Also found in: Medical.
Related to Invokana: canagliflozin, metformin, Victoza
Translations

canagliflozin

n canagliflozina
References in periodicals archive ?
A total of 469 patients with type 2 diabetes inadequately controlled on the combination of metformin (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and sulfonylurea (maximal or near-maximal effective dose) participated in a 26-week, double-blind, placebocontrolled study to evaluate the efficacy and safety of INVOKANA in combination with metformin and sulfonylurea.
Limited Tenders are invited for Invokana 100Mg (Johnson & Johnson) - 400.
Growth was primarily driven by new products including OLYSIO/SOVRIAD (simeprevir), for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA for type 2 diabetes; and IMBRUVICA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Janssen), today announced real-world and clinical findings showing that people with type 2 diabetes treated with INVOKANA (canagliflozin) achieved greater blood glucose control and were more likely to stay on therapy than were those treated with dipeptidyl peptidase-4 (DPP-4) inhibitors, a common class of medicines for type 2 diabetes that includes Januvia (sitagliptin).
Even with a pretty extensive set of postmarketing studies, getting Invokana onto the U.
Janssen Research & Development, LLC (Janssen), today announced that 18 presentations on INVOKANA (canagliflozin) will be featured at the American Diabetes Associations (ADA) 76th Scientific Sessions, June 10-14 in New Orleans.
Food and Drug Administration (FDA) has approved INVOKAMET, a fixed-dose combination therapy of INVOKANA (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes.
Limited Tenders are invited for Supply of Invokana 100Mg J&J - 200.
Limited Tenders are invited for Invokana Tab (Johnson & Johnson) - 450.
M2 EQUITYBITES-March 14, 2018-Janssen Pharmaceutical reveals results of new analysis of Invokana